Louise Emmett
Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.
Overview
Louise Emmett (St Vincent's Hospital, Sydney) was principal investigator of ENZA-p, the ANZUP trial showing that adding 177Lu-PSMA-617 to enzalutamide delays progression in castration-resistant prostate cancer, and led the PRIMARY study of PSMA PET for diagnosis. She co-leads the ANZUP theranostics programme and writes widely used guidance on PSMA PET reporting.
| Title | Journal | Year |
|---|---|---|
| [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial | Lancet Oncology | 2024 |
| The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY) | European Urology | 2021 |
Similar pages
not linked directly; found by shared links- PersonA. Oliver Sartor
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters) and the tags prostate, radioligand.
- PersonShahneen Sandhu
Shares 177Lu-PSMA-617 (Pluvicto) with olaparib, TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA, Lutetium-177 vipivotide tetraxetan.
- PersonDeclan G. Murphy
Shares European Urology, PSMA, PSMA PET, Prostate cancer and the tag prostate.
- PersonRahul Aggarwal
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonSilke Gillessen
Shares European Urology, Prostate cancer and the tag prostate.
- PersonMichael J. Morris
Shares TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- PersonMichael Hofman
Shares TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET.